Combination immunotherapy treatment effective before lung cancer surgery
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
The findings, published today in Cancer Discovery, were first presented at the American Association for Cancer Research...
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue...
Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe...
CPRIT awards $2.5 million to support MD Anderson cancer research
The University of Texas MD Anderson Cancer Center was awarded $2.5 million today from the Cancer Prevention and Research Institute of Texas (CPRIT) to support cancer research projects across the institution.
Four of the five grants awarded to MD Anderson today are CPRIT High-Impact/High-Risk Research Awards, which provide short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute...
Immunotherapy before surgery induces complete response in more than half of patients with common skin cancer in international study
ABSTRACT 789O
In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3%...
MD Anderson receives CPRIT funding to expand access to cervical cancer screening and treatment in Texas
The University of Texas MD Anderson Cancer Center today was awarded $2.5 million in continued funding from the Cancer Prevention and Research...
Poziotinib is active in EGFR exon 20 mutant non-small cell lung cancer with efficacy highly dependent on insertion location
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations...
Androgen receptor signaling contributes to targeted therapy resistance in melanoma
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from...
Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers, including glioblastoma
ABSTRACTS: 2006, 2511
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of...
Immunotherapy before surgery associated with improved survival for soft-tissue sarcoma
ABSTRACT: LBA11501
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses...